Pfizer (PFE), Merck (MRK) win FDA expansion for Padcev plus Keytruda in all MIBC patients

Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. (TSE: 4503, OTC: ALPMF, OTC: ALPMY), and Merck & Co., Inc. (NYSE: MRK) announced on July 10, 2026 that the United States Food and Drug Administration (FDA) has expanded the label for Padcev (enfortumab vedotin-ejfv) in combination with either Keytruda (pembrolizumab) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility, extending the prior November 2025 approval that had been limited to cisplatin-ineligible patients and establishing the combination as the first platinum-free treatment regimen approved for muscle-invasive bladder cancer patients scheduled for surgical bladder removal.

The expanded approval is supported by results from the pivotal Phase 3 EV-304 trial, also known as KEYNOTE-B15, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, in which the Padcev plus pembrolizumab combination reduced the risk of death by 35 percent compared with neoadjuvant chemotherapy, produced a pathological complete response rate of 55.8 percent at the time of surgery compared with 32.5 percent in the chemotherapy arm, and delivered an event-free survival of 79.4 percent at two years compared with 66.2 percent for standard care. Pfizer Inc. shares traded at approximately 24.25 dollars on the New York Stock Exchange on the announcement day, largely unchanged intraday, while Merck & Co., Inc. shares traded near recent levels reflecting a market that had substantially anticipated the label expansion based on the strong EV-304 datapoint disclosed at ASCO GU earlier in 2026.

The commercial architecture of the announcement rests on the Padcev collaboration between Pfizer Inc. and Astellas Pharma Inc. that operates as a 50/50 profit-share arrangement following Pfizer Inc.’s completion of its Seagen acquisition on December 14, 2023, and the Padcev plus Keytruda clinical collaboration that Seagen and Astellas Pharma Inc. established with Merck & Co., Inc. prior to the Seagen acquisition. Pfizer Inc. Executive Vice President and Chief U.S. Commercial Officer Aamir Malik framed the approval as a historic turning point for muscle-invasive bladder cancer treatment, noting that the combination has established itself as the standard of care for first-line therapy of advanced bladder cancer and is now moving into earlier, potentially curative-intent settings.

What does the July 10 FDA expansion actually change for the Padcev-Keytruda commercial trajectory

The expanded label doubles the addressable patient population for the Padcev plus Keytruda perioperative regimen by extending eligibility from cisplatin-ineligible muscle-invasive bladder cancer patients to all muscle-invasive bladder cancer patients who are candidates for bladder removal surgery. That population expansion is analytically significant because cisplatin-eligible patients represent approximately half of the muscle-invasive bladder cancer population, and the previous November 2025 approval had left this larger patient cohort dependent on cisplatin-based chemotherapy regimens that carry substantial toxicity, limited efficacy, and long-term quality of life burdens for patients undergoing curative-intent bladder removal surgery. The commercial addressable market for the perioperative Padcev plus Keytruda regimen therefore approximately doubles as a consequence of the label expansion.

The addressable United States patient population for the expanded indication is analytically material. Approximately 80,000 new bladder cancer cases are diagnosed in the United States each year, and approximately 25 percent of those cases involve muscle-invasive disease, translating to roughly 20,000 muscle-invasive bladder cancer candidates for bladder removal surgery annually. Prior to the expanded label, the cisplatin-ineligible subset of that population represented approximately half of the total, or roughly 10,000 potential candidates for the perioperative Padcev plus Keytruda regimen. The label expansion adds the remaining approximately 10,000 cisplatin-eligible patients annually, and per-patient annual therapeutic economics for the perioperative regimen at established Padcev plus Keytruda pricing support a materially larger commercial opportunity than the pre-expansion patient base.

The commercial implication for Pfizer Inc., Astellas Pharma Inc., and Merck & Co., Inc. is that peak sales expectations for the perioperative muscle-invasive bladder cancer indication should be revised upward by sell-side analysts across the coming weeks as the label expansion is incorporated into revenue models. Prior consensus expectations for the Padcev franchise had assumed a substantial contribution from the perioperative indication but had generally reflected the cisplatin-ineligible-only patient scope. The expanded label supports an incremental peak sales opportunity in the several hundred million dollars to potentially over one billion dollar range across the combined Padcev and Keytruda franchise economics, though the specific quantification will depend on penetration assumptions, competitive dynamics with adjacent regimens, and net pricing outcomes.

Why is the 35 percent reduction in mortality risk from EV-304 the analytically important number

The 35 percent reduction in the risk of death demonstrated in the EV-304 trial, corresponding to a hazard ratio of 0.65 for overall survival compared with neoadjuvant chemotherapy, is the specific efficacy datapoint that anchors the commercial and analytical case for the label expansion. Overall survival benefits of this magnitude are unusual in perioperative oncology trials, particularly in comparisons against established chemotherapy standards of care that themselves have demonstrated meaningful survival benefits over historical treatment approaches. A 35 percent mortality risk reduction translates into clinically meaningful patient benefit that individual physicians, tumor boards, and multidisciplinary treatment teams can readily incorporate into treatment recommendations, and it supports both prescriber adoption and payer coverage decisions.

The composition of the efficacy result is at least as important as the headline hazard ratio. Event-free survival at two years of 79.4 percent for Padcev plus Keytruda versus 66.2 percent for standard care represents an approximately 13 percentage point absolute improvement in the specific metric that captures both disease recurrence and survival outcomes, which are the endpoints that matter most in perioperative oncology. The pathological complete response rate of 55.8 percent at the time of surgery versus 32.5 percent for chemotherapy provides an early biomarker that supports the survival benefit story and gives clinicians confidence that the treatment effect is genuine and durable. The combination of pathological complete response, event-free survival, and overall survival benefits together delivers the multi-endpoint efficacy case that supports strong physician conviction on the new regimen.

The read-across for the broader antibody-drug conjugate development landscape is meaningful. Enfortumab vedotin-ejfv targets Nectin-4 through the antibody component and delivers the vedotin cytotoxic payload directly to tumor cells expressing the target antigen, and the combined approach with Keytruda leverages the specific mechanism of action of the ADC with the checkpoint inhibitor immunotherapy in a way that appears to deliver a genuinely additive or synergistic clinical benefit. If the EV-304 result pattern is replicated in other tumor types where Nectin-4 is expressed and where the ADC plus checkpoint inhibitor combination is being explored, the commercial trajectory for antibody-drug conjugate development across the oncology industry could accelerate substantially. Multiple ADCs are in development at AstraZeneca, Daiichi Sankyo Company, Gilead Sciences, Merck & Co., Inc., and various smaller biotech operators, and the EV-304 datapoint supports investor confidence in the broader ADC investment thesis.

How does the platinum-free positioning transform the muscle-invasive bladder cancer treatment paradigm

Platinum-based chemotherapy has been the standard of care for perioperative treatment of muscle-invasive bladder cancer for approximately three decades, and its clinical limitations are well-documented and clinically significant. Cisplatin-based regimens deliver meaningful efficacy but carry substantial toxicity including renal function impairment, ototoxicity, peripheral neuropathy, myelosuppression, and quality of life burdens that limit tolerability particularly in older patients and patients with pre-existing comorbidities. Approximately half of muscle-invasive bladder cancer patients are considered cisplatin-ineligible due to renal function impairment, cardiac conditions, hearing loss, performance status, or other clinical factors, and prior to the November 2025 Padcev plus Keytruda approval this substantial patient population had no established curative-intent perioperative treatment alternative to surgery alone.

The strategic significance of the July 10 label expansion is that the treatment paradigm shift from platinum-containing to platinum-free perioperative therapy is now available across the entire muscle-invasive bladder cancer patient population rather than being confined to the cisplatin-ineligible subgroup. Clinical practice guidelines developed by organisations including the National Comprehensive Cancer Network, the European Association of Urology, and the American Urological Association will now incorporate the expanded Padcev plus Keytruda indication into treatment recommendations, and the specific pace at which those guideline updates translate into prescriber practice change will shape the commercial trajectory over the coming quarters.

The competitive positioning of Padcev plus Keytruda against the established cisplatin-based regimens is now genuinely paradigm-shifting. Physicians choosing between the two treatment approaches will be evaluating a 35 percent mortality risk reduction demonstrated in a head-to-head Phase 3 trial against the established but toxic chemotherapy standard, and the analytical case for choosing the platinum-free regimen is substantial for cisplatin-eligible patients who would otherwise be steered toward chemotherapy. The specific rate at which cisplatin-eligible patients migrate to the Padcev plus Keytruda regimen will depend on physician conviction, patient preference, payer coverage, and specific institutional treatment pathway design, but the direction of migration is now clearly toward the platinum-free approach.

What role does Astellas Pharma play in the Padcev economic split and Pfizer oncology growth

Astellas Pharma Inc. holds a 50/50 profit-share arrangement with Pfizer Inc. on the Padcev franchise, following Pfizer Inc.’s completion of its Seagen acquisition on December 14, 2023 for approximately 43 billion United States dollars. The original Padcev collaboration was established between Seagen Inc. and Astellas Pharma Inc. prior to the Pfizer Inc. acquisition, and Pfizer Inc. inherited the Astellas Pharma Inc. relationship as part of the Seagen transaction. The 50/50 economic split means that both Pfizer Inc. and Astellas Pharma Inc. share equally in the commercial upside from the expanded muscle-invasive bladder cancer label, and both companies bear equal commercial development responsibility across the shared commercial infrastructure.

The strategic significance for Pfizer Inc. is that Padcev represents one of the highest-value assets acquired through the Seagen acquisition and continues to validate the commercial thesis behind the substantial 43 billion dollar acquisition price. Padcev global sales were approximately 1.85 billion United States dollars in 2025 with strong sequential growth momentum from the 2023 first-line advanced urothelial carcinoma approval with Keytruda, and the expanded muscle-invasive bladder cancer label supports continued top-line growth through 2026, 2027, and beyond. For a Pfizer Inc. that is navigating the post-COVID commercial slowdown and preparing for patent expirations across multiple products, the Padcev franchise contribution to oncology revenue growth is materially important to the overall corporate revenue trajectory.

The strategic significance for Astellas Pharma Inc. is that Padcev has become one of the company’s most important oncology franchises and validates its ADC development strategy. Astellas Pharma Inc. holds a Chief Growth Officer position for its broader oncology franchise development, and the Padcev franchise growth trajectory supports both the current revenue trajectory and the credibility of the broader ADC platform investment. Astellas Pharma Inc. also holds shares of Merck & Co., Inc.’s Keytruda commercial partnership on the Padcev plus Keytruda specific combination, though the specific economic terms of that additional arrangement are not fully public. The combined commercial architecture positions Astellas Pharma Inc. as a materially larger oncology operator than its scale would otherwise suggest.

Why does the label expansion pressure AstraZeneca’s Imfinzi perioperative MIBC franchise

AstraZeneca plc’s Imfinzi (durvalumab) became the first immunotherapy approved for perioperative muscle-invasive bladder cancer in March 2025, based on the NIAGARA Phase 3 trial. The Imfinzi perioperative regimen requires cisplatin-based chemotherapy alongside the immunotherapy, which limits its addressable patient population to cisplatin-eligible patients and creates specific competitive positioning against the Padcev plus Keytruda platinum-free approach. Prior to the July 10 label expansion, Imfinzi held the first-mover advantage in perioperative immunotherapy for cisplatin-eligible muscle-invasive bladder cancer, and the AstraZeneca plc commercial infrastructure had been focused on establishing prescriber adoption and payer coverage for the Imfinzi combination regimen.

The competitive positioning shift that the July 10 approval creates is that Imfinzi’s cisplatin-only constraint now becomes a specific commercial disadvantage rather than a market-defining advantage. Physicians treating cisplatin-eligible muscle-invasive bladder cancer patients previously had to choose between the Imfinzi plus chemotherapy regimen and surgery alone, but they now have the Padcev plus Keytruda platinum-free alternative that has demonstrated a 35 percent mortality risk reduction and materially higher pathological complete response rates. The commercial dynamic favours the platinum-free regimen for patients and physicians who prefer to avoid the toxicity burden of cisplatin-based chemotherapy, and AstraZeneca plc’s Imfinzi franchise will need to defend its market share through longer-term data, specific patient population targeting, or pricing and access strategies.

The read-through to AstraZeneca plc’s broader immunotherapy franchise is worth noting. Imfinzi across all indications generated approximately 4.5 to 5 billion United States dollars in 2025 revenue, and the perioperative muscle-invasive bladder cancer indication was expected to be a meaningful growth contributor through 2026 and 2027. The Padcev plus Keytruda label expansion compresses that growth expectation and creates specific analytical headwinds for the AstraZeneca plc oncology portfolio. Combined with the CARDIO-TTRansform Phase 3 trial failure for the Wainua ATTR cardiomyopathy indication that AstraZeneca plc announced on July 9, 2026, the pharmaceutical company is navigating a specific two-day window of competitive pressure across multiple key franchises.

How does the Keytruda Qlex subcutaneous formulation support Merck’s patent cliff response

Keytruda Qlex is the subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa-pmph that Merck & Co., Inc. developed to extend the Keytruda franchise beyond the intravenous formulation’s patent expiration in 2028. The FDA approval of Keytruda Qlex was included as an alternative to Keytruda in the July 10 muscle-invasive bladder cancer label expansion, meaning that prescribers can choose either the intravenous Keytruda or the subcutaneous Keytruda Qlex in combination with Padcev for perioperative treatment. That specific formulation flexibility supports the Merck & Co., Inc. commercial strategy of migrating patients toward the Qlex subcutaneous formulation as it becomes the more convenient administration option and as the intravenous formulation approaches patent expiration.

The strategic significance of the Keytruda Qlex formulation for Merck & Co., Inc. is that it represents one of the most important patent extension strategies in the pharmaceutical industry. Keytruda generated approximately 32 to 33 billion United States dollars in 2025 revenue and is the largest single product in the global oncology market, and the intravenous formulation patent expiration in 2028 represents a substantial revenue at risk from biosimilar competition. Successful migration of the Keytruda patient base to the Qlex subcutaneous formulation protects the majority of the revenue stream through the subcutaneous formulation patent protection window, which extends materially beyond the intravenous formulation patent expiration.

The inclusion of Keytruda Qlex in the muscle-invasive bladder cancer perioperative label expansion is one specific example of the broader Merck & Co., Inc. strategy of embedding the Qlex formulation across the Keytruda label. As Merck & Co., Inc. continues to expand the Keytruda label across additional indications and continues to include Keytruda Qlex as an alternative formulation, the commercial infrastructure for the subcutaneous formulation builds progressively across the prescriber base, payer contracting, and specialty pharmacy channels. That infrastructure building through 2026 and 2027 positions Merck & Co., Inc. to execute the Qlex migration efficiently as the 2028 patent expiration approaches, protecting the franchise from the worst-case biosimilar erosion scenarios that had been embedded in some sell-side models.

What are the safety, competitive, and payer risks that could compress the extended MIBC opportunity

The safety profile of Padcev in combination with Keytruda remains an important commercial consideration. Padcev carries specific warnings around skin reactions, hyperglycemia, peripheral neuropathy, pneumonitis, ocular disorders, and infusion site reactions, and it has known risks including harm during pregnancy. The safety profile in the perioperative setting has been characterised in the EV-304 trial data and is broadly consistent with the safety experience in the metastatic setting, but the specific patient selection dynamics and treatment monitoring requirements will shape the practical rate at which physicians adopt the regimen across community oncology practice as well as academic medical centres. Any post-marketing safety signal that emerges as the regimen scales into broader use could pressure adoption.

The competitive risk architecture is more nuanced than the immediate Imfinzi comparison suggests. Multiple additional immunotherapy and ADC combinations are in development for muscle-invasive bladder cancer perioperative treatment, including trials from Bristol-Myers Squibb Company, Roche Holding AG, and various biotech operators. Additional Phase 3 data readouts across the coming 12 to 24 months could introduce new competitive dynamics or reinforce the Padcev plus Keytruda market position, and the specific commercial trajectory for the expanded label will depend on how the competitive landscape evolves. Padcev plus Keytruda’s first-in-class positioning as a platinum-free perioperative regimen is a durable competitive advantage but not a permanent one.

The payer coverage architecture for the expanded label is a specific commercial variable that will shape the practical revenue realisation. Commercial payers, Medicare Part B and Part D, and Medicaid programmes will need to update coverage policies for the expanded muscle-invasive bladder cancer indication, and any prior authorisation restrictions or clinical criteria requirements that emerge could affect the pace of prescriber adoption. Given the strength of the EV-304 clinical evidence and the platinum-free positioning against cisplatin-based chemotherapy, payer coverage is likely to be broadly supportive, but specific coverage details will vary across payer categories and will influence the specific revenue trajectory.

Key takeaways on what the Padcev-Keytruda MIBC approval signals for oncology investors and pharma peers

• The United States Food and Drug Administration expanded the label for Padcev in combination with Keytruda or Keytruda Qlex as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility on July 10, 2026, establishing the combination as the first platinum-free perioperative regimen approved for the full muscle-invasive bladder cancer patient population.
• The expanded approval builds on the November 2025 approval for cisplatin-ineligible muscle-invasive bladder cancer patients and effectively doubles the addressable patient population from approximately 10,000 cisplatin-ineligible patients per year in the United States to approximately 20,000 total muscle-invasive bladder cancer surgical candidates annually.
• The EV-304 pivotal Phase 3 trial, also known as KEYNOTE-B15, delivered a 35 percent reduction in the risk of death with a hazard ratio of 0.65, event-free survival of 79.4 percent at two years versus 66.2 percent for standard chemotherapy, and pathological complete response of 55.8 percent versus 32.5 percent at the time of surgery.
• Pfizer Inc. and Astellas Pharma Inc. share Padcev economics on a 50/50 profit-share basis following Pfizer Inc.’s completion of its Seagen acquisition on December 14, 2023 for approximately 43 billion United States dollars, and Padcev global sales of approximately 1.85 billion United States dollars in 2025 support continued franchise growth from the expanded muscle-invasive bladder cancer indication.
• The label expansion pressures AstraZeneca plc’s Imfinzi perioperative muscle-invasive bladder cancer franchise, which received the first perioperative immunotherapy approval in March 2025 but requires cisplatin-based chemotherapy and therefore serves only cisplatin-eligible patients, compressing its commercial advantage against the platinum-free Padcev plus Keytruda alternative.
• The AstraZeneca plc competitive pressure compounds against the July 9, 2026 CARDIO-TTRansform Phase 3 trial failure for Wainua (eplontersen) in ATTR cardiomyopathy that AstraZeneca plc had been developing with Ionis Pharmaceuticals, creating a two-day competitive pressure window across multiple oncology and cardiovascular franchise commitments.
• The inclusion of Keytruda Qlex, the subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa-pmph, in the expanded label supports Merck & Co., Inc.’s patent extension strategy ahead of the 2028 intravenous Keytruda patent expiration, and it builds subcutaneous formulation infrastructure across the prescriber base and payer contracting network.
• Pfizer Inc. shares traded at approximately 24.25 dollars on the New York Stock Exchange on the announcement day, largely unchanged intraday, reflecting a market that had substantially anticipated the label expansion based on the strong EV-304 data disclosed at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.
• The commercial architecture of the Padcev franchise, combining an antibody-drug conjugate targeting Nectin-4 with the Keytruda checkpoint inhibitor immunotherapy, supports investor confidence in the broader antibody-drug conjugate investment thesis being pursued by AstraZeneca plc, Daiichi Sankyo Company Limited, Gilead Sciences, Inc., and multiple additional pharmaceutical operators alongside Pfizer Inc. and Merck & Co., Inc.
• Execution and commercial risks include safety monitoring in the broader post-marketing use, competitive pressure from additional immunotherapy and ADC combinations in Phase 3 development for muscle-invasive bladder cancer, and payer coverage architecture that will shape the practical revenue realisation from the expanded label across the coming quarters.